Associazione Italiana Ematologia Oncologia Pediatrica
Quick facts
Phase 3 pipeline
- ATRA + IDA · Oncology
ATRA (all-trans retinoic acid) differentiates acute promyelocytic leukemia cells while IDA (idarubicin) induces DNA damage and apoptosis in leukemic blasts.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Associazione Italiana Ematologia Oncologia Pediatrica portfolio CI brief
- Associazione Italiana Ematologia Oncologia Pediatrica pipeline updates RSS
Frequently asked questions about Associazione Italiana Ematologia Oncologia Pediatrica
What is Associazione Italiana Ematologia Oncologia Pediatrica's pipeline?
Associazione Italiana Ematologia Oncologia Pediatrica has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include ATRA + IDA.
Related
- Sector hub: All tracked pharma companies